Literature DB >> 22307202

High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro.

Masayoshi Yamaguchi1, M Neale Weitzmann.   

Abstract

Vitamin D is essential for optimal calcium absorption needed for maintaining normal bone mineral density (BMD). Consequently, vitamin D-deficiency leads to poorly mineralized bone with diminished strength and load bearing capacity. Surprisingly, several animal and clinical studies have identified suppressive effects of high dose vitamin D supplementation on bone formation. These data suggest that while vitamin D is necessary for basal bone homeostasis, excessive concentrations may be detrimental to the skeleton. To further examine the direct effects of high dose vitamin D on the function of osteoblasts we differentiated primary osteoblast precursors and MC3T3 preosteoblastic cells, in the presence of supraphysiological doses of the active metabolite, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]. In vitro osteoblast mineralization was potently suppressed by high dose 1,25(OH)2D3. To investigate the mechanism we used a bioassay to examine nuclear factor-κB (NF-κB) activation in MC3T3 cells. Although NF-κB agonists are generally potent inhibitors of osteoblast differentiation, surprisingly, 1,25(OH)2D3 dose-dependently suppressed, rather than stimulated, NF-κB activation. Interestingly, 1,25(OH)2D3 also suppressed Smad activation induced by the osteoblast commitment and differentiation factors transforming growth factor-β (TGF-β) and bone morphogenetic protein 2 (BMP2), which may account for the inhibitory activities of 1,25(OH)2D3 on mineralization. Our data suggest that vitamin D has complex pleiotropic effects on osteoblast signal transduction. As the net balance of high dose 1,25(OH)2D3 appears to be an inhibitory action on osteoblasts, our data suggest that the therapeutic value of vitamin D to maximize bone mass through indirect actions on calcium absorption may need to be carefully balanced with potential inhibitory direct effects on mineralizing cells. Our data suggest that indiscriminate over-dosing may be detrimental to bone formation and optimal concentrations need to be established for humans in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307202     DOI: 10.3892/ijmm.2012.900

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  13 in total

1.  Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice.

Authors:  John A Eisman; Roger Bouillon
Journal:  Bonekey Rep       Date:  2014-02-05

2.  Vitamin D endocrine system and osteoblasts.

Authors:  Marjolein van Driel; Johannes P T M van Leeuwen
Journal:  Bonekey Rep       Date:  2014-02-05

3.  Effect of retinoic acid and vitamin D3 on osteoblast differentiation and activity in aging.

Authors:  Michela Bosetti; Maurizio Sabbatini; Anna Calarco; Alessia Borrone; Gianfranco Peluso; Mario Cannas
Journal:  J Bone Miner Metab       Date:  2015-02-18       Impact factor: 2.626

4.  Bone Loss in HIV Infection.

Authors:  Caitlin A Moran; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Curr Treat Options Infect Dis       Date:  2017-02-23

5.  Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats.

Authors:  Jing Sun; Bao Sun; Wei Wang; Xiuchun Han; Hongrui Liu; Juan Du; Wei Feng; Bo Liu; Norio Amizuka; Minqi Li
Journal:  J Mol Histol       Date:  2016-06-02       Impact factor: 2.611

Review 6.  Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review.

Authors:  Malcolm D Kearns; Jessica A Alvarez; Vin Tangpricha
Journal:  Endocr Pract       Date:  2014-04       Impact factor: 3.443

7.  Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification.

Authors:  Baisheng Fu; Hongwei Wang; Jinhua Wang; Ivana Barouhas; Wanqing Liu; Adam Shuboy; David A Bushinsky; Dongsheng Zhou; Murray J Favus
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

Review 8.  Vitamin D and gene networks in human osteoblasts.

Authors:  Jeroen van de Peppel; Johannes P T M van Leeuwen
Journal:  Front Physiol       Date:  2014-04-09       Impact factor: 4.566

9.  Vitamin-D receptor agonist calcitriol reduces calcification in vitro through selective upregulation of SLC20A2 but not SLC20A1 or XPR1.

Authors:  M P Keasey; R R Lemos; T Hagg; J R M Oliveira
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

10.  Super pharmacological levels of calcitriol (1,25-(OH)2D3) inhibits mineral deposition and decreases cell proliferation in a strain dependent manner in chicken mesenchymal stem cells undergoing osteogenic differentiation in vitro.

Authors:  Vivek V Pande; Kapil C Chousalkar; Marie S Bhanugopan; Jane C Quinn
Journal:  Poult Sci       Date:  2015-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.